![image0[4051].png](https://static.wixstatic.com/media/6c2ba7_62b050e548d3442282068e7faba98ee4~mv2.png/v1/fill/w_131,h_131,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/image0%5B4051%5D.png)
Regulatory Science and Quality Control Mandates
To facilitate international expansion, 2026 has seen the introduction of stringent new regulations focused on the safety and standardization of herbal products.
The 2026 Production Provisions: Effective March 1, 2026, new rules from the NMPA mandate "Good Agricultural Practice" (GAP) standards for all Chinese medicinal materials. This aims to eliminate issues with heavy metal contamination and pesticide residues that historically hindered export.
National Reimbursement Inclusion: In China, the 2026 National Reimbursement Drug List (NRDL) now includes 1,396 proprietary Chinese medicines, ensuring that these therapies are affordable and integrated into the mainstream insurance system alongside chemical drugs.
Evidence-Based Evaluation Models: International experts are calling for evaluation models that respect TCM’s holistic nature—using "real-world effectiveness studies" rather than forcing herbal formulas into clinical trial paradigms designed for single-molecule drugs.